Ignite Creation Date:
2025-12-25 @ 2:40 AM
Ignite Modification Date:
2025-12-26 @ 1:19 AM
Study NCT ID:
NCT03497533
Status:
UNKNOWN
Last Update Posted:
2019-09-06
First Post:
2018-02-11
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Treatment of Refractory/Relapsed Non-Hodgkin Lymphoma With TriCAR-T_CD19
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D008228', 'term': 'Lymphoma, Non-Hodgkin'}], 'ancestors': [{'id': 'D008223', 'term': 'Lymphoma'}, {'id': 'D009370', 'term': 'Neoplasms by Histologic Type'}, {'id': 'D009369', 'term': 'Neoplasms'}, {'id': 'D008232', 'term': 'Lymphoproliferative Disorders'}, {'id': 'D008206', 'term': 'Lymphatic Diseases'}, {'id': 'D006425', 'term': 'Hemic and Lymphatic Diseases'}, {'id': 'D007160', 'term': 'Immunoproliferative Disorders'}, {'id': 'D007154', 'term': 'Immune System Diseases'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE1', 'PHASE2'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'NA', 'maskingInfo': {'masking': 'NONE'}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'SINGLE_GROUP'}, 'enrollmentInfo': {'type': 'ESTIMATED', 'count': 6}}, 'statusModule': {'overallStatus': 'UNKNOWN', 'lastKnownStatus': 'RECRUITING', 'startDateStruct': {'date': '2018-08-03', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2019-09', 'completionDateStruct': {'date': '2020-12-31', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2019-09-05', 'studyFirstSubmitDate': '2018-02-11', 'studyFirstSubmitQcDate': '2018-04-10', 'lastUpdatePostDateStruct': {'date': '2019-09-06', 'type': 'ACTUAL'}, 'studyFirstPostDateStruct': {'date': '2018-04-13', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2020-12-31', 'type': 'ESTIMATED'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Safety (Incidence of treatment-related adverse events as assessed by CTCAE v4.0)', 'timeFrame': '30 Days', 'description': 'Incidence of treatment-related adverse events as assessed by CTCAE v4.0'}], 'secondaryOutcomes': [{'measure': 'Complete response rate[CR] (Complete response rate per the revised International Working Group (IWG) Response Criteria for Malignant Lymphoma)', 'timeFrame': '12 months', 'description': 'Complete response rate per the revised International Working Group (IWG) Response Criteria for Malignant Lymphoma'}, {'measure': 'Partial response rate [PR] (Partial response rate per the revised International Working Group (IWG) Response Criteria for Malignant Lymphoma)', 'timeFrame': '12 months', 'description': 'Partial response rate per the revised International Working Group (IWG) Response Criteria for Malignant Lymphoma'}, {'measure': 'Duration of Response （The time from response to relapse or progression）', 'timeFrame': '12 months', 'description': 'The time from response to relapse or progression'}, {'measure': 'Progression Free Survival（The time from the first day of treatment to the date on which disease progresses.）', 'timeFrame': '12 months', 'description': 'The time from the first day of treatment to the date on which disease progresses.'}, {'measure': 'Overall Survival（The number of patient alive, with or without signs of cancer）', 'timeFrame': '24 months', 'description': 'The number of patient alive, with or without signs of cancer'}]}, 'oversightModule': {'oversightHasDmc': True, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'keywords': ['CD19', 'CAR-T', 'TriCAR-T-CD19', 'non-Hodgkin lymphoma', 'NHL'], 'conditions': ['Non-hodgkin Lymphoma,B Cell']}, 'referencesModule': {'references': [{'pmid': '21832238', 'type': 'BACKGROUND', 'citation': 'Kalos M, Levine BL, Porter DL, Katz S, Grupp SA, Bagg A, June CH. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med. 2011 Aug 10;3(95):95ra73. doi: 10.1126/scitranslmed.3002842.'}, {'pmid': '28129122', 'type': 'RESULT', 'citation': 'Locke FL, Neelapu SS, Bartlett NL, Siddiqi T, Chavez JC, Hosing CM, Ghobadi A, Budde LE, Bot A, Rossi JM, Jiang Y, Xue AX, Elias M, Aycock J, Wiezorek J, Go WY. Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma. Mol Ther. 2017 Jan 4;25(1):285-295. doi: 10.1016/j.ymthe.2016.10.020. Epub 2017 Jan 4.'}, {'pmid': '28925994', 'type': 'RESULT', 'citation': 'Neelapu SS, Tummala S, Kebriaei P, Wierda W, Gutierrez C, Locke FL, Komanduri KV, Lin Y, Jain N, Daver N, Westin J, Gulbis AM, Loghin ME, de Groot JF, Adkins S, Davis SE, Rezvani K, Hwu P, Shpall EJ. Chimeric antigen receptor T-cell therapy - assessment and management of toxicities. Nat Rev Clin Oncol. 2018 Jan;15(1):47-62. doi: 10.1038/nrclinonc.2017.148. Epub 2017 Sep 19.'}]}, 'descriptionModule': {'briefSummary': 'This is a single arm, open-label, single-center, phase 1/2 study, to determine the safety and efficacy of TriCAR-T-CD19, an autologous tri-functional anti-CD19 chimeric antigen receptor (CAR)-positive T cell therapy, in refractory/Relapsed Non-Hodgkin Lymphoma (NHL).', 'detailedDescription': 'The tri-functional anti-CD19 chimeric antigen receptor contains an anti-CD19 scFv, a PD-L1 blocker, and a cytokine complex, enabling the TriCAR-T-CD19 to simultaneously targeting the CD19 positive NHL，blocking the inhibitory PD-L1 signal and stimulating T/NK cell activation and expansion.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'maximumAge': '68 Years', 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': "Inclusion Criteria:\n\n1. All subjects must personally sign and date the consent form before initiating any study specific procedures or activities;\n2. All subjects must be able to comply with all the scheduled procedures in the study;\n3. Histologically or cytologically confirmed CD19 positive non-Hodgkin lymphoma;\n4. Chemotherapy-refractory disease, defined as one or more of the following: Relapsed in 6 months after most recent therapy; Progressive disease in the standard R-CHOP or CHOP chemotherapy; Disease progression or relapsed in ≤12 months of ASCT (must have biopsy proven recurrence in relapsed subjects); If salvage therapy is given post-ASCT, the subject must have had no response to or relapsed after the last line of therapy.\n5. No available standard therapy;\n6. At least one measurable lesion per revised IWG Response Criteria;\n7. Aged 18 to 68 years;\n8. Expected survival ≥12 weeks;\n9. Eastern cooperative oncology group (ECOG) performance status of ≤2;\n10. Systematic usage of immunosuppressive drug or corticosteroid must have been stopped for more than 4 weeks;\n11. All other treatment induced adverse events must have been resolved to ≤grade 1;\n12. Laboratory tests must fulfill the following criteria: ANC ≥ 1000/uL, HGB \\>70g/L, Platelet count ≥ 50,000/uL, Creatinine clearance ≤1.5 ULN, Serum ALT/AST ≤2.5 ULN, Total bilirubin ≤1.5 ULN (except in subjects with Gilbert's syndrome);\n13. Female must be not pregnant during the study.\n\nExclusion Criteria:\n\n1. History of malignancy other than nonmelanoma skin cancer or carcinoma in situ (e.g. cervix, bladder, breast) or follicular lymphoma unless disease free for at least 3 years;\n2. History of allogeneic stem cell transplantation;\n3. Prior other CAR therapy or other genetically modified T cell therapy;\n4. Presence of fungal, bacterial, viral, or other infection that is uncontrolled or requiring IV antimicrobials for management. Simple UTI and uncomplicated bacterial pharyngitis are permitted if responding to active treatment;\n5. Subjects with detectable cerebrospinal fluid malignant cells, or brain metastases, or with a history of CNS lymphoma, cerebrospinal fluid malignant cells or brain metastases;\n6. Lactating women;\n7. Active infection with hepatitis B (HBsAG positive) or hepatitis C virus (anti-HCV positive);\n8. Subjects need systematic usage of corticosteroid;\n9. History of any gene therapy;\n10. Subjects need systematic usage of immunosuppressive drug;\n11. Known history of infection with HIV;\n12. Planed operation, history of other related disease, or any other related laboratory tests restrict patients for the study;\n13. Other reasons the investigator think the patient may not be suitable for the study."}, 'identificationModule': {'nctId': 'NCT03497533', 'acronym': 'Trident19-H', 'briefTitle': 'Treatment of Refractory/Relapsed Non-Hodgkin Lymphoma With TriCAR-T_CD19', 'organization': {'class': 'INDUSTRY', 'fullName': 'Timmune Biotech Inc.'}, 'officialTitle': 'TriCAR-T-CD19 Adoptive Immunotherapy for CD19-positive Refractory/Relapsed Non-Hodgkin Lymphoma', 'orgStudyIdInfo': {'id': 'ChiCTR1800014528'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'TriCAR-T-CD19', 'description': 'Tri-functional anti-CD19 chimeric antigen receptor transduced autologous T cells will be administered intravenously', 'interventionNames': ['Biological: TriCAR-T-CD19']}], 'interventions': [{'name': 'TriCAR-T-CD19', 'type': 'BIOLOGICAL', 'description': 'A conditioning chemotherapy regimen of fludarabine and cyclophosphamide will be administered followed by a single infusion of CAR transduced autologous T cells administered intravenously at a target dose of 0.5-1 x 10\\^6 CAR+ T cells/kg', 'armGroupLabels': ['TriCAR-T-CD19']}]}, 'contactsLocationsModule': {'locations': [{'zip': '410005', 'city': 'Changsha', 'state': 'Hunan', 'status': 'RECRUITING', 'country': 'China', 'contacts': [{'name': 'Jianjun Chen', 'role': 'CONTACT', 'phone': '+86 0731 83928147'}, {'name': 'Ming Zhou', 'role': 'CONTACT', 'email': 'zhouming_0321@163.com', 'phone': '+86 0731 83928145'}], 'facility': "Hunan Provincial People's Hospital", 'geoPoint': {'lat': 28.19874, 'lon': 112.97087}}], 'centralContacts': [{'name': 'Ming Zhou', 'role': 'CONTACT', 'email': 'zhouming_0321@163.com', 'phone': '+86 0731 83928147'}, {'name': 'Bin Gao', 'role': 'CONTACT', 'email': 'bin.gao@timmune.com', 'phone': '+86 022 59060560', 'phoneExt': '803'}], 'overallOfficials': [{'name': 'Ming Zhou', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': "Hunan Provincial People's Hospital"}]}, 'ipdSharingStatementModule': {'ipdSharing': 'UNDECIDED'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Timmune Biotech Inc.', 'class': 'INDUSTRY'}, 'collaborators': [{'name': "Hunan Provincial People's Hospital", 'class': 'OTHER'}], 'responsibleParty': {'type': 'SPONSOR'}}}}